LivaNova plc Aktie
LivaNova plc Aktie
Die LivaNova plc Aktie rutscht heute ab, verliert -1,75 %.
Die LivaNova plc Aktie erhält starke Unterstützung mit mehreren Buy- und keiner Sell-Einschätzung.
Ein Kursziel von 66 € für LivaNova plc impliziert ein leicht positives Wachstum gegenüber dem aktuellen Kurs von 56.0 €.
Was spricht für und gegen LivaNova plc in den nächsten Jahren?
Pro
?
M****
?
M************
?
U****************
Kontra
?
A****************
?
L*********** I********** f** d** n******* J****
?
W******* i* V********
Sag uns deine Meinung, um die 'Wisdom of the Crowds' zu nutzen
Rendite von LivaNova plc im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| LivaNova plc | -1,75 % | -2,61 % | 12,90 % | 32,08 % | 19,66 % | -18,84 % | -10,40 % |
| Neogen Corp. | 3,54 % | 5,41 % | -1,68 % | -23,53 % | -36,07 % | -69,41 % | -57,20 % |
| Bio-Rad Labs Inc. A | 0,37 % | 4,54 % | -3,79 % | -20,78 % | -7,39 % | -45,18 % | - |
| Merit Medical Systems | 2,70 % | 2,01 % | 11,76 % | -1,30 % | 11,76 % | 54,47 % | 55,26 % |
Kommentare
LivaNova is a leader in Extra-Corporeal Membrane Oxygenation. A Theraphy that has established itself during Swineflue, Birdflue, SARS, MERS in the past. Well positioned as an Italian manufacturer the current Corona Epidemic will boost LivaNovas profits.
Strong expected performance in Cardiovascular Segment. Upside potential through treatment of Corona Virus with Extracorporeal Life Support. LivaNova is well positioned for that.
News
LivaNova Reports First-Quarter 2024 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended March 31, 2024 and raised full-year 2024 revenue and adjusted diluted earnings
LivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Ahmet Tezel, Ph.D., will join the Company as Chief Innovation Officer (CINO), effective May 13, 2024. In
LivaNova Issues Notice to U.S. Patients Regarding Cybersecurity Incident
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that its wholly-owned U.S. subsidiary, LivaNova USA, Inc., is providing notice to U.S. patients regarding a